Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2018

View Archived Issues

Combined delivery of CLN1 gene therapy proven to extend lifespan in INCL mice

Sienna announces first patient dosed in phase I/II study of SNA-125 for psoriasis

Bristol-Myers Squibb and Nektar Therapeutics enter global collaboration for NKTR-214

Sanofi reports pipeline highlights of fourth quarter 2017

We want your opinion - complete the TRDN user survey

Meaningful activity seen with BC-819 plus BCG in bladder cancer

Preliminary results presented for BGB-A317 in patients with urothelial carcinoma

PICP and MMP-1 identified as biomarkers of Fabry disease cardiomyopathy

Pfizer's PF-04965842 granted FDA breakthrough therapy designation for atopic dermatitis

SanBio and Teijin to terminate SB-623 licensing agreement

Veru presents preclinical data for VERU-111 in prostate cancer models

Therachon starts first-in-human trial of TA-46 for achondroplasia

FDA approves Erleada for non-metastatic castration-resistant prostate cancer

Sumitomo, Nitto announce positive topline results for patch formulation of antipsychotic blonanserin

EMA grants ATMP classification to Regeneus' Progenza

Imugene to advance anti-PD-1 mimotope vaccine into preclinical development

Vectus Biosystems patents compounds for pulmonary fibrosis

Ginkgo divulges novel HBV antigen secretion inhibitors

Chengdu Easton Pharmaceutical discloses IP receptor agonists

Seattle Genetics opens phase I study of SGN-CD48A in multiple myeloma

Novartis studies LRX-712 in patients with osteoarthritis

Boehringer Ingelheim Pharma & Co. patents GOAT inhibitors

New CCR4 antagonists presented by FLX Bio

Primary endpoint not met in Aramchol study in patients with HIV-associated lipodystrophy and NAFLD

Oxford BioMedica enters collaboration and license agreement with Bioverativ in hemophilia

FDA grants de novo request for commercialization of Banyan BTI test for traumatic brain injury

Santhera licenses POL-6014 from Polyphor

FDA awards orphan drug designation to selumetinib for neurofibromatosis type 1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...